BYDUREON BCise Injectable medicine now available in the US for type-2 diabetes patients

11 Jan 2018

The new formulation is proven to reduce blood sugar levels and may have the added benefit of weight loss.

AstraZeneca has announced that BYDUREON BCise (exenatide extended-release) injectable suspension 2 mg is now available in pharmacies across the US. BYDUREON BCise was recently approved by the FDA for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral antidiabetic medicines in addition to diet and exercise, to improve glycemic control.

BYDUREON BCise Injectable medicine now available in the US for type-2 diabetes patients

BYDUREON BCise is a new formulation of BYDUREON (exenatide extended-release) injectable suspension 2 mg in an improved once-weekly, single-dose autoinjector device. It is designed for patient ease and convenience in a pre-filled device with a pre-attached hidden needle. The new formulation of BYDUREON BCise is proven to reduce blood sugar levels and may have the added benefit of weight loss, although not a weight loss medicine. The medication is administered in three simple steps – mix, unlock, inject.

Rod Wooten, Vice President, Cardiovascular and Metabolic Diseases, AstraZeneca, said: "We're pleased that BYDUREON BCise is now available for adults with type 2 diabetes. This new formulation helps to provide consistent glycemic control, in addition to the powerful HbA1c reductions and added benefit of weight loss, now in a simply improved device."

Across two clinical trials, average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds were achieved when used as monotherapy or as an add-on to metformin, a sulfonylurea, a thiazolidinedione, or any combination of two of these oral antidiabetic medicines at 28 weeks. The most common adverse reactions reported in ≥5% of patients in clinical trials were nausea (8.2%) and adverse events associated with injection-site nodules (10.5%).

Virginia Valentine APRN, BC-ADM, CDE, FAADE, said: "Managing type 2 diabetes is complicated and requires daily attention to meal planning, exercise and medications. A once-weekly prescription option in an easy-to-use device, like BYDUREON BCise, can help simplify a patient's regimen and help them achieve diabetes control goals."

Read More

Related tags

Market News

Related news

SIRIO Pharma opens multimillion gummy production plant

SIRIO Pharma opens multimillion gummy production plant

18 Oct 2018

The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.

Read more 
Tjoapack and Veratrak launch EPOCH initiative

Tjoapack and Veratrak launch EPOCH initiative

17 Oct 2018

The virtual platform is designed to allow the healthcare industry to effectively research and explore new technologies that will help to shape the future of the pharmaceutical supply chain.

Read more 
Cambrex invests $3m to upgrade generic API manufacturing facilities at Milan site

Cambrex invests $3m to upgrade generic API manufacturing facilities at Milan site

16 Oct 2018

The investment increases the overall capacity and capabilities of the facility, and its flexibility.

Read more 
Particle Sciences to open new commercial facility

Particle Sciences to open new commercial facility

15 Oct 2018

New facility will offer customers the full range of services from development through to commercial-scale manufacturing

Read more 
Generics companies to move away from little white pills

Generics companies to move away from "little white pills"

14 Oct 2018

Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.

Read more 
Pharma manufacturers warned to invest in continuous manufacturing

Pharma manufacturers warned to invest in continuous manufacturing

11 Oct 2018

CMOs hit by reduced volumes of opioid manufacturing from DEA quota changes, but cannabis sales to ignite.

Read more 
New portable and ready-to-use upper respiratory drug delivery solution

New portable and ready-to-use upper respiratory drug delivery solution

11 Oct 2018

PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.

Read more 
CPhI Worldwide announces the winners  of the 15th Pharma Awards

CPhI Worldwide announces the winners of the 15th Pharma Awards

10 Oct 2018

17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.

Read more 
CMOs to benefit from double digit approvals for ADCs in the next 3 years

CMOs to benefit from double digit approvals for ADCs in the next 3 years

9 Oct 2018

Therapeutic ADC market expected to reach $4 billion by 2023.

Read more 
Micro-Sphere increases capsule filling capacity

Micro-Sphere increases capsule filling capacity

8 Oct 2018

The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.

Read more